Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder

Ilan A. Kerman1†*, René Bernard2†, William E. Bunney3, Edward G. Jones4, Alan F. Schatzberg5, Richard M. Myers6, Jack D. Barchas7, Huda Akil7, Stanley J. Watson8 and Robert C. Thompson9

1 Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA
2 Department of Experimental Neurology, Charité Hospital, Berlin, Germany
3 Department of Psychiatry, University of California, Irvine, CA, USA
4 Center for Neuroscience, University of California, Davis, CA, USA
5 Stanford University, Palo Alto, CA, USA
6 HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
7 Weill School of Medicine, Cornell University, New York, NY, USA
8 Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
9 Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA

Edited by:
Igor Ponomarev, The University of Texas at Austin, USA
Reviewed by:
Ken Sugino, Brandeis University, USA
Michael Oldham, University of California San Francisco, USA

*Correspondence:
Ilan A. Kerman, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, 7120 7th Avenue South, Birmingham, AL 35294, USA
E-mail: kerman@uab.edu
†Ilan A. Kerman and René Bernard have contributed equally to this work.

INTRODUCTION

Major depressive disorder (MDD) is among the most debilitating neuropsychiatric illnesses. With an estimated lifetime prevalence of 16%, MDD is characterized by a high burden of morbidity caused by co-occurrence of physical ailments together with a high level of mortality due to suicide (Carney et al., 1993; Frank and Thase, 1999; Penninx et al., 2001; Kessler et al., 2003; Brown et al., 2004; Taylor and MacQueen, 2006). Despite increased public awareness and enormous research efforts, the etiology and pathophysiology of MDD remain poorly understood, and few fully effective treatments are available. The most compelling theory of the etiology of MDD has been the monoaminergic theory of depression, which posits a deficit in the concentration of monoaminergic neurotransmitters such as serotonin (5-HT) in the brains of depressed patients (Bunney and Davis, 1965; Schildkraut, 1965; Coppen, 1968; Lapin and Oxenkrug, 1969; Hirschfeld, 2000; Leonard, 2000). Consistent with this theory, first-line treatments for MDD include medications that increase absolute concentrations of monoaminergic neurotransmitters at the synapse, such as selective 5-HT reuptake inhibitors (SSRIs) or tricyclic antidepressants (Leonard, 2000; Blier, 2001). The theory also involves an assumption that, conversely, depletion of monoaminergic transmitters can induce a depressive state (Goodwin and Bunney, 1971; Neumeister, 2003).

The single largest source of serotonergic innervation of the forebrain is the dorsal raphe nucleus (DR; Azmitia, 1999). Via its dense innervation of forebrain limbic and cortical regions, the DR regulates affect, cognition, reward, and homeostasis, all of which...
are disturbed in MDD (Lowry et al., 2008). Previous studies have documented extensive alterations in the serotoninergic system in the depressed brain, including alterations in 5-HT receptor binding, gene expression, protein levels, and reuptake transporter function in both the forebrain and the brainstem (Arango et al., 1996a,b, 2001, 2002; Klimek et al., 1997; Underwood et al., 1999; Zhu et al., 1999; Ordway et al., 2003; Boldrini et al., 2005, 2008; Bach-Mizrachi et al., 2006, 2008; Matthews and Harrison, 2012); these data suggest a disruption of 5-HT circuits both at the level of the cell body as well as the terminal. Consistent with this notion, a number of studies have documented gene expression alterations in the DR in depression (Arango et al., 2001; Boldrini et al., 2005; Bach-Mizrachi et al., 2006, 2008; Goswami et al., 2010).

All of these previous studies were hypothesis driven and focused solely on expression of genes that directly regulate 5-HT neurotransmission or 5-HT receptor signaling. Because MDD is a multifactorial and is likely a polygenic disorder, a dysregulated 5-HT pharmacologic state alone cannot account for all DR abnormalities. Therefore, the current study utilized an unbiased microarray-based approach to identify novel expression alterations of genes in the DR in MDD in postmortem human tissue. Our data indicate alterations in the expression of multiple transcriptional regulators that have the potential to impact diverse cellular functions within the DR and contribute to the etiology of MDD.

MATERIALS AND METHODS

SUBJECTS

Acquisition of postmortem human brain samples were conducted at the University of California at Irvine Brain Bank. Tissue processing, and procedures for microarray experiments have been previously described (Evans et al., 2004; Tomita et al., 2004; Choudary et al., 2005; Bernard et al., 2011). Brainstem tissue blocks were collected from depressed subjects (n = 13; antemortem diagnoses of MDD) and from non-psychiatric controls (C; n = 8; Table 1). Because extensive agonal stress and low tissue pH dramatically impact profiles of gene expression in the brain (Li et al., 2004; Tomita et al., 2004; Atz et al., 2007), blocks were collected only from subjects that experienced sudden deaths (agonal factor score of 0), and only samples from brains with pH > 6.6 were included in further processing (Table 1).

TISSUE PROCESSING

Tissue blocks were sectioned on a cryostat in a coronal plane to a thickness of 10 μm and immediately thaw mounted onto Super-Frost glass slides (Fisher Scientific, Pittsburgh, PA, USA). Each slide contained one section, and slides were stored at −80°C. Every 50th slide was then processed for radioactive in situ hybridization (ISH) to detect the distribution of serotonin transporter (SERT) mRNA as previously described (Lopez-Figueroa et al., 2004; Bernard et al., 2009). Specificity of the ISH probe was validated using sense controls and tissue pretreatment with RNase (data not shown). Processed tissue sections were apposed to radiosensitive film (BioMax MR film, Kodak1) for 7 days to delineate the anatomical boundaries of the DR.

Slides processed for ISH were then stained with a modified Klüver–Barrera method, which included staining with cresyl violet and luxol fast blue to identify neurons and fibers of passage. Distribution of SERT ISH signal was used in combination with histologically stained slides to delineate the regions of interest and to facilitate anatomical alignment of the specimens. This approach ensured that we sampled from the same antero-posterior subregion of DR common among all subjects in our cohort.

SERT autoradiograms and histologically stained slides were digitized and used to guide laser capture microdissection (LCM) on adjacent unstained tissue sections. It was important to use unstained tissue for LCM so as to preserve RNA integrity for the downstream gene expression assays. At the same time, use of the histologically and neurochemically stained adjacent guide sections allowed precise anatomical delineation of DR and related brainstem nuclei (Bernard et al., 2009, 2011). Samples were harvested from the middle-caudal DR, with bilateral collection from three consecutive tissue sections at three levels separated by 500 μm (total of nine DR nuclei). Position of anatomical landmarks, including the fourth ventricle and medial longitudinal fasciculus, from histochemically stained images, and SERT ISH signal were visually projected onto sections used for LCM. Regions in unstained sections that corresponded to boundaries of the DR were then microdissected under a 4× objective using CapSure macrocaps (Applied Biosystems) as previously described (Bernard et al., 2009). We have previously validated neuroanatomical precision of this approach (Bernard et al., 2009).

RNA ISOLATION AND AMPLIFICATION

RNA extraction and isolation were performed with the use of the PicoPure RNA Isolation Kit (Molecular Devices, Sunnyvale, CA, USA) according to manufacturer’s instructions, including DNase treatment. For each nucleus, RNA extracts from the three LCM caps from the same subject were combined before purification. RNA quantity and quality were evaluated using the 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA quality and its suitability for downstream gene expression analyses were determined from BioAnalyzer electropherograms according to the method of Schoor et al. (2003). Accordingly, extracted RNA samples were considered acceptable for downstream gene expression analyses if they met the following criteria: (1) <65% of the total area under the electropherogram curve was between the end of the marker peak and the beginning of the 18S rRNA peak, and (2) >4% of the total area was under the 28S rRNA peak (Schoor et al., 2003; Bernard et al., 2009). All of our samples met these exclusion criteria and were included in further analyses and processing.

RNA samples were subjected to two rounds of amplification (RiboAmp OA RNA Kit, Molecular Devices) and subsequent biotin labeling (Perkin Elmer, Wilhalm, MA, USA) according to manufacturers’ instructions. A portion of the second strand cDNA synthesis reaction product (i.e., amplified double-stranded cDNA), generated from RNA following in vitro transcription at the end of the first round of amplification was set aside for quantitative real-time PCR (qPCR; see below). After two amplification rounds, 15 μg of biotinylated amplified RNA from each DR sample were then hybridized to HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA) per manufacturer’s instructions.
Table 1 | Demographic and clinical characteristics of subjects included in the study.

| Diagnosis | Subject | Race     | Age  | Sex | PMI (hours) | Agonal factor | Brain PH | Cause of death | SSRI at time of death |
|-----------|---------|----------|------|-----|-------------|---------------|----------|----------------|-----------------------|
| Control   | 2169    | Caucasian| 18   | M   | 22          | 0             | 6.97     | Accident       | No                    |
| Control   | 2292    | Caucasian| 55   | M   | 15          | 0             | 6.89     | Sudden med. cond. | No                    |
| Control   | 2805    | Caucasian| 45   | M   | 21          | 0             | 6.86     | Sudden med. cond. | No                    |
| Control   | 3228    | Pacific Islander | 39  | M   | 18.15      | 0             | 6.81     | Sudden med. cond. | No                    |
| Control   | 3516    | Caucasian| 41   | M   | 22.5        | 0             | 7.01     | Sudden med. cond. | No                    |
| Control   | 3519    | African American | 65  | M   | 13.5        | 0             | 6.88     | Sudden med. cond. | No                    |
| Control   | 3520    | Caucasian| 74   | F   | 18.5        | 0             | 7.21     | Sudden med. cond. | No                    |
| Control   | 3588    | Caucasian| 56   | M   | 24.5        | 0             | 6.98     | Sudden med. cond. | No                    |
| MDD       | 2208    | Caucasian| 72   | F   | 21          | 0             | 7.13     | Suicide        | No                    |
| MDD       | 2267    | Caucasian| 19   | M   | 18          | 0             | 7.11     | Suicide        | No                    |
| MDD       | 3064    | Caucasian| 46   | M   | 27          | 0             | 6.91     | Sudden med. cond. | No                    |
| MDD       | 3169    | Caucasian| 35   | M   | 24.75       | 0             | 7.04     | Accident       | No                    |
| MDD       | 3365    | Caucasian| 47   | M   | 29          | 0             | 7.25     | Suicide        | No                    |
| MDD       | 3426    | Caucasian| 63   | M   | 28.5        | 0             | 7.17     | Sudden med. cond. | No                    |
| MDD       | 3303    | Caucasian| 49   | M   | 27          | 0             | 7.19     | Suicide        | No                    |
| MDD       | 3398    | Caucasian| 80   | F   | 15          | 0             | 6.68     | Sudden med. cond. | No                    |
| MDD       | 2315    | Caucasian| 58   | M   | 24          | 0             | 6.93     | Suicide        | Yes                   |
| MDD       | 2944    | Caucasian| 52   | M   | 16          | 0             | 6.82     | Sudden med. cond. | Yes                   |
| MDD       | 3071    | Caucasian| 49   | M   | 31          | 0             | 7        | Unknown        | Yes                   |
| MDD       | 3168    | Caucasian| 39   | M   | 275         | 0             | 6.79     | Suicide        | Yes                   |
| MDD       | 3481    | Caucasian| 66   | M   | 32          | 0             | 7.05     | Sudden med. cond. | Yes                   |

All subjects in the cohort were well matched for age, gender, race, post-mortem interval, agonal factor, and pH. F, female; M, male; MDD, major depressive disorder; cond., condition; PMI, post-mortem interval; SSRI, selective serotonin reuptake inhibitor.

**GENE EXPRESSION MICROARRAYS**

Affymetrix CEL files were analyzed with the use of the Robust Multi-Chip Average (RMA) and the Affymetrix Microarray Suite 5 calls (MASSCALLS) algorithm. Affymetrix chip description files were replaced by custom probe set mapping files that independently reassigned all Affymetrix probe sets to an updated UniGene cluster (Dai et al., 2005). Log2-based microarray intensity values were used for statistical analyses.

Gene expression differences were evaluated by Student’s t-tests and were considered to be significant if: (1) the p-values were ≤ 0.05, (2) expression was detected in ≥ 50% of arrays in C or MDD groups according to the MASSCALLS algorithm, and (3) a gene’s log2 intensity value was ≥ 4.0 according to RMA algorithm. Fold change differences were calculated from group averages of microarray intensity values. Pearson’s correlations (two-tailed p-values) between microarray and qPCR results were computed using MS Excel 2010.

**QUANTITATIVE REAL-TIME PCR**

We used SYBR Green chemistry for qPCR validation of microarray results. Genomic DNA and mRNA sequences were downloaded from NCBI Entrez Gene3,4 and Primer3 software (Rozen and Skaletsky, 2000) was used to design primers to: (1) anneal within 500 bp of the 3’ end, (2) generate a single amplicon 75–150 bp in size, and (3) amplify all splice variants for the gene of interest. For each amplicon, predicted secondary structure was minimized with the use of DNA Mfold (Zuker, 2003). Primer sequences are listed in Table 2. Primer performance was validated via serial dilutions and amplification efficiency testing by using human genomic DNA and/or amplified cDNA from human brainstem sections [source of input DNA did not impact amplification efficiency (data not shown)].

Reactions were carried out in 96-well PCR plates (Bio-Rad, Hercules, CA, USA). Each well contained 5 µl of amplified double-stranded cDNA (50 pg/µl), which was set aside after the second strand cDNA synthesis performed following in vitro transcription at the end of first round of mRNA amplification (as described above). Concentration of amplified cDNA was quantified for each sample by using Quant-iT PicoGreen dsDNA Kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. Each qPCR well also contained 5 µl of forward and reverse strand primers (final concentration 500 nM) and 10 µl of iQ SYBR Green Supermix (Bio-Rad).

A Bio-Rad iCycler (Bio-Rad) was utilized for amplifications, which were performed by using a touchdown PCR approach: denaturation at 95°C for 1 min 45 s, followed by ten cycles of (1) denaturing at 95°C for 15 s, (2) annealing at 65–60°C for 15 s, and (3) extension at 72°C for 15 s. Annealing temperature was decreased at each step of the cycle by 0.5°C from a maximum of 65°C to the final temperature of 60°C. This was followed by 45 cycles of (1) denaturing at 95°C for 15 s, (2) annealing at 60°C for 15 s, and (3) extension at 72°C for 15 s. Fluorescence was quantified after the extension step by using a FAM-490 or SYBR-488 detection protocol at a peak
Table 2 | Primers used for qPCR.

| Gene name | Gene symbol | Accession number | Primers (forward, reverse) | Tm (˚C) | Product size (bp) |
|-----------|-------------|------------------|----------------------------|---------|------------------|
| Transducer of ERBB2, 1 | TOB1 | NM_005749 | TTTTCATTTGCCAACCAAGC | 60.98   | 115              |
|  |  |  | AAAATACGCACTCATGTCCCTG | 60.08 | 113              |
| Nuclear receptor subfamily 4, group A, member 2 | NR4A2 | NM_173173 | ACACCTGCAACATCTCCTTG | 60.81   | 147              |
|  |  |  | TGCATGCAAGTTGTTGTGAC | 59.02 | 147              |
| CD69 molecule | CD69 | NM_001781 | AGACAGTCTCTTTCTGATG | 59.14   | 138              |
|  |  |  | TGCACATACATATGTCAC | 59.58 | 138              |
| Early growth response 1 | EGR1 | NM_001964 | TAGGCGGCGATTTTTGTATG | 60.95   | 110              |
|  |  |  | TATCCCCTGGCGATAATAAGG | 59.76 | 110              |
| TCDD-inducible poly(ADP-ribose) polymerase | TIPARP | NM_015508 | TTCCTCAGTTCAGAGGTCG | 57.82   | 139              |
|  |  |  | AAACATTACCAGGAGAGCTTGG | 59.65 | 139              |
| Protein phosphatase 1, regulatory (inhibitor) subunit 3C | PPP1R3C | NM_003053 | TGTGCACAACATCTGAGG | 60.72   | 138              |
|  |  |  | TACCTTCCACATGCGACA | 59.96 | 138              |
| Adrenomedullin | ADM | NM_001124 | GTGAATGTCTCAGCGAGGTG | 59.42   | 120              |
|  |  |  | TCGTGTTTCTCTCCCTCAC | 59.09 | 120              |
| CXCR7 chemokine (C-X-C motif) receptor 7 | CXCR7 | NM_020311 | ATATGTGTGGAGAGCTATG | 58.03   | 110              |
|  |  |  | CAAAACCTGAAGCTGCTACAC | 58.95 | 110              |
| Nuclear receptor subfamily 4, group A, member 3 | NR4A3 | NM_006981 | TGTGCAACACATGAGAGG | 60.72   | 120              |
|  |  |  | GCATGTGTGGAGAGCTACAC | 58.95 | 120              |
| Solute carrier family 19 (thiamine transporter), member 2 | SLC19A2 | NM_006996 | TTGACATCAGAACTGAGG | 59.72   | 75               |
|  |  |  | TGACATCAGAACTGAGG | 59.96 | 75               |
| Eukaryotic translation elongation factor 1 alpha 1 | EEF1A1 | NM_001402 | TTGACATCAGAACTGAGG | 59.99   | 138              |
|  |  |  | TGACATCAGAACTGAGG | 59.47 | 138              |

bp, base pairs; Tm, melting temperature.

RESULTS

ORGANIZATION OF THE DORSAL RAPHE

Our initial studies examined ISH autoradiograms to delineate the organization of the DR and the neighboring 5-HT cell groups in the human brainstem. Figure 1 illustrates a series of SERT autoradiograms from a representative control subject, with images arranged from the anterior (Figure 1A) to the posterior (Figure 1O) pole of the DR in 500 µm increments between adjacent panels. At its anterior pole, the DR was barely noticeable and was defined by loosely packed and scattered SERT signal (Figures 1A–C); moving more posteriorly, the DR was defined by fan-like shape with loosely packed horns located dorsolaterally to its vertically oriented midline division (Figures 1D–F). At its middle and middle-caudal levels (Figures 1G–L), the dorsolateral horns narrowed and increased their density of hybridization signal, and the overall shape of the DR resembled the letter V as indicated by arrowheads in Figure 1K. At the more caudal levels, the DR became loosely packed with ill-defined borders and was contiguous with dispersed 5-HT cell groups located ventrally (Figures 1M–O).

These rostro-caudal differences in the organization of the DR correspond with functional and connectional differences (Abrams et al., 2004; Lowry et al., 2008). Tract-tracing studies in animal models have demonstrated that the caudal portion of the DR receives strong afferent inputs from several forebrain limbic regions, including medial prefrontal cortex, habenula, and the hypothalamus, while giving rise to projections to the hippocampus.
Based on these observations we collected our samples from the depressed suicide individuals (Bach-Mizrachi et al., 2006, 2008). Previous post-mortem human brain studies have also demonstrated more robust gene expression differences within the middle-caudal DR, as opposed to its more rostral subdivisions, in depressed suicide individuals (Wyss et al., 1979; Lee et al., 2003; Waselus et al., 2009, 2011). In our control samples we observed 48.5 ± 3.27% (mean ± SEM; 95% CI: 46.0–50.9%) of signal <18S area of electropherogram, and 7.2 ± 1.5% (95% CI: 4.4–10.1%) within the 28S peak. In the MDD samples these measures were: 50.5 ± 1.6% (95% CI: 48.9–52.1%) and 7.5 ± 0.7% (95% CI: 5.6–9.4), respectively. Since group differences were not significant (p > 0.05) and observed values were all well above inclusion thresholds, these data indicate that extracted RNA was compatible with downstream gene expression profiling and qPCR quantification.

OVERALL MICROARRAY RESULTS

Overall expression intensity for the microarray data from RNA log2 values was 6.57 ± 0.01 in the C group and 6.58 ± 0.01 in the MDD group. Raw detection call rates calculated from MASS5CALLS output were 49.0 ± 1.4% for the C group and 47.9 ± 1.5% for the MDD group. We found no significant differences in RNA intensity values or MASS5CALLS detection call rates (p > 0.05).

The average Pearson correlation among all of the samples was 0.95 ± 0.007. One of the samples (subject 3365) had an average correlation of 0.83 with the other samples. However, removing this sample from our analyses, did not significantly impact the largest changes in gene expression that we detected (see Tables 3 and 4). Heat map of differentially expressed genes included in functional pathways analysis (see below) revealed a clear separation between C and MDD samples (Figure 2).

FUNCTIONAL PATHWAYS

To evaluate differential expression we used the MASS5CALLS algorithm, which computes through selective match/mismatch ratio, the certainty with which a transcript is detected on a microarray chip. Genes that had log2, RNA mean intensity values ≥4.0, exhibited MASS5CALLS detection call rates ≥50% in C or MDD group, were upregulated or downregulated by ≥1.1-fold at p < 0.05 level were included. Using these criteria, a total of 292 genes were found to be differentially expressed between C and MDD samples, and of these, 126 genes were downregulated and 166 were upregulated (see Supplementary Materials). We utilized Ingenuity Pathway Analysis3 to identify functional pathways that are impacted by these expression changes. A total of 21 canonical pathways were identified as significantly involved (p < 0.05); these pathways were grouped into 8 functional categories: n-glycan biosynthesis, metabolism, axonal guidance signaling, mitochondrial dysfunction, intracellular signaling, transcription regulators, NRF2-mediated oxidative stress response, and cell cycle regulation (Table 3).

TRANSCRIPTION REGULATORS AND DOWNSTREAM TARGETS

As the next step, we used an unbiased analysis approach to detect genes that exhibited the largest differences in expression between C and MDD samples. Microarray data were filtered for genes that were identified as detected by MASS5CALLS algorithm on

3http://www.ingenuity.com/products/pathways_analysis.html
Table 3 | Functional groups that showed significant alterations in gene expression.

| N-glycan biosynthesis | Intracellular signaling | Transcription regulators | NRF2-mediated oxidative stress response | Cell cycle regulation |
|-----------------------|-------------------------|--------------------------|----------------------------------------|-----------------------|
| B4GALT6 ↓             | ANLN ↓                  | EGR1 ↓                   | MAF ↓                                  | HNRNPA1 ↓            |
| MAN2A1 ↓              | PPP1R3C ↓               | TOB1 ↓                   | GSTT1 ↑                                | CCNE2 ↓              |
| B4GALT2 ↑             | ITPR1 ↓                 | NR4A2 ↓                  | VCP ↑                                  | CND2 ↓              |
| DOLK ↑                | GNAQ ↓                  | NR4A3 ↓                  | CYP42A1 ↑                              | TIN2 F ↓            |
| RPN1 ↑                | GNA13 ↓                 | NR4A3 ↓                  | CDC34 ↑                                | MAX ↑               |

Metabolism

| GLUL ↓                | RDX ↓                   | SMAD6 ↑                  | SAT1 ↓                                 |
|                      |                         |                          |                                       |
| SDHC ↓               | PIP4K2B ↑               |                          |                                       |
| BDH1 ↑               | PARP6A ↑                |                          |                                       |
| DGKQ ↑               | CDH2 ↑                  |                          |                                       |
| LIPE ↑               | TOLLIP ↑                |                          |                                       |
| RND1 ↓               | VAMP2 ↑                 |                          |                                       |
| RND2 ↓               | NPT2 ↑                  |                          |                                       |
| RNX1 ↓               | NPTR ↓                  |                          |                                       |
| PKCαD                 |                          |                          |                                       |

Axonal guidance signaling

| CXCR4 ↓              |                          |                          |                                       |
| ARHGEF7 ↓            |                          |                          |                                       |
| VEGFC ↑              |                          |                          |                                       |
| SEMA3G ↑             |                          |                          |                                       |
| KLCI ↑               |                          |                          |                                       |
| RND1 ↑               |                          |                          |                                       |
| ARPC1B ↑             |                          |                          |                                       |
| LINGO1 ↑             |                          |                          |                                       |
| PIK3CD ↑             |                          |                          |                                       |

Mitochondrial dysfunction

| F1S1 ↑               |                          |                          |                                       |
| NDUFB3 ↑             |                          |                          |                                       |
| COX6A1 ↑             |                          |                          |                                       |
| PRDX5 ↑              |                          |                          |                                       |
| PSEN2 ↑              |                          |                          |                                       |

Using Ingenuity Pathway Analysis we identified a total of 21 canonical pathways that exhibited significant alterations in expression (p < 0.05). These pathways belonged to eight distinct functional groups (bold headings): within each functional group genes that were significantly altered in the MDD group as compared to the C group are listed with arrows indicating upregulation or downregulation in expression. Bold italics indicate genes that were among those that showed the largest changes in expression (see Table 4).

at least 50% of arrays in either group, had log₂ RMA mean intensity values ≥4.0, and showed ≥1.4-fold changes in expression at p < 0.05. This approach revealed alterations in the expression of 16 transcripts in MDD versus C. Expression of 13 of these genes was downregulated, including: TOB1, NR4A2, EGR1, CD69, TIPARP, ADM, PPP1R3C, CXCR7, NR4A3, SLC19A2, EEF1A1, CCDC58, and SYT14 (Table 4). Expression of two genes, GSTT1 and PYROXD1, was upregulated, while that of a non-protein coding RNA CHST9-AS1 was downregulated in the MDD group (Table 4).

Examination of the top genes within the framework of pathway analysis revealed that three functional groups – (1) Intracellular Signaling, (2) Transcription Regulators, and (3) NRF2-Mediated Oxidative Stress Response, contained genes with the largest (≥1.40-fold change) changes in expression. Of these, the Transcription Regulators functional group contained the greatest number of such genes, which included: EGR1, TOB1, NR4A2, and NR4A3 (Tables 3 and 4).

Confirmation of expression changes by qPCR was conducted on samples from all subjects and included 11 transcripts. The changes in expression detected by both microarrays and by qPCR were always in the same direction (Table 4). We observed a significant (p < 0.05) correlation between microarray and qPCR results for all genes, with the exception of NR4A3 (Table 4). Changes in the expression of five transcripts (TOB1, NR4A2, EGR1, TIPARP, and ADM) reached statistical significance (p ≤ 0.05) as detected by qPCR, whereas changes in the expression of three other genes (CD69, PPP1R3C, and CXCR7) exhibited a trend toward significance (p ≤ 0.1; Table 4).

Using IPA functional networks feature, we extended our analysis to downstream targets of TOB1, NR4A2, and EGR1. Genes were included in this analysis if they were detected in ≥50% of C or MDD microarrays and were altered in their expression by 1.1-fold or greater at the level of p < 0.05. In the case of TOB1, this analysis revealed a downregulation of SMAD2-SMAD4-TOB and SMAD3-SMAD4-TOB transcriptional regulation complexes along with the downregulation of CCNE2, a cell cycle regulator that belongs to the Cyclin E complex (Figure 3). Expression of multiple genes was downregulated downstream of EGR1, including that of: CCND2, CSDA (which has a reciprocal relationship with EGR1), GADD45B, PPP1R3C, and THRB. Additionally, expression of CHGA, THR2, ALOX5, and CDKN1C was upregulated downstream from EGR1. In the case of NR4A2, its downstream targets of ADM and NR4A3 were downregulated, while CDKN1C and SLC6A3 were upregulated. Interestingly, NR4A3 exhibits a reciprocal relationship with NR4A2, while CDKN1C expression is regulated by both NR4A2 and EGR1 (Figure 3).

To determine the pattern of expression within the DR of EGR1, NR4A2, and ADM (a downstream target of NR4A2), we performed ISH in three of the control subjects on tissue sections that contained the middle-caudal DR (Figure 4). These genes were widely expressed at relatively low levels, as is true of other transcriptional regulators (Kerman et al., 2012). These ISH data suggest that EGR1, NR4A2, and ADM are expressed within a variety of cell types, but are enriched in their expression within the DR (Figure 4). Based on this hybridization pattern, it is likely that these genes impact a wide variety of cellular functions and neuronal circuits.

**IMPACT OF MEDICATION**

To assess potential medication effects, we examined expression levels of EGR1, TOB1, NR4A2, and ADM in MDD patients who were prescribed SSRIs at the time of death (MDD+SSRI) and in those who were not (MDD−). Because microarrays and qPCR are complementary measures of gene expression we used a meta-analytic approach of z-score normalization to combine microarray
Table 4 | Results of microarray and qPCR experiments.

| Ref seq ID    | Gene name                      | Symbol | Gene expression Microarray | qPCR | Array-qPCR |
|--------------|--------------------------------|--------|----------------------------|------|------------|
|              |                                |        | Log 2 mean intensity       | p-Value | F-change | p-Value | F-change | p-Value | r       |
| NM_005749    | Transducers of ERBB2, 1        | TOB1   | 10.1                       | 0.034 | −1.95     | 0.021   | −1.67     | <0.0001 | 0.90    |
| NM_173173    | Nuclear receptor subfamily 4, group A, member 2 | NR4A2  | 6.3                        | 0.007 | −1.87     | 0.032   | −3.57     | <0.01   | 0.63    |
| NM_001964    | Early growth response 1        | EGR1   | 8.8                        | 0.023 | −1.71     | 0.046   | −2.96     | <0.01   | 0.59    |
| NM_001781    | CD69 molecule                  | CD69   | 5.3                        | 0.036 | −1.72     | 0.076   | −2.68     | <0.05   | 0.51    |
| NM_015508    | TCDD-inducible poly(ADP-ribose) polymerase | TiPARP | 9.0                        | 0.012 | −1.60     | 0.038   | −2.26     | <0.0001 | 0.93    |
| NM_001124    | Adrenomedullin                 | ADM    | 9.3                        | 0.008 | −1.59     | 0.025   | −2.81     | <0.0001 | 0.70    |
| NM_005398    | Protein phosphatase 1, regulatory (inhibitor) subunit 3C | PPP1R3C | 8.9                        | 0.010 | −1.59     | 0.061   | −2.03     | <0.0001 | 0.95    |
| NM_020311    | CXCR7 chemokine (C–X–C motif) receptor 7 | CXCR7  | 8.7                        | 0.049 | −1.57     | 0.098   | −1.67     | <0.0001 | 0.90    |
| NM_173199    | Nuclear receptor subfamily 4, group A, member 3 (NR4A3) | NR4A3  | 5.6                        | 0.001 | −1.54     | 0.127   | −1.51     | 0.46    | 0.17    |
| NM_006996    | Solute carrier family 19 (thiamine transporter), member 2 | SLC19A2 | 7.0                        | 0.041 | −1.53     | 0.125   | −1.58     | <0.0001 | 0.87    |
| NM_001402    | Eukaryotic translation elongation factor 1 alpha 1 | EEF1A1 | 8.4                        | 0.016 | −1.42     | 0.117   | −2.36     | <0.0001 | 0.58    |
| NM_001017928 | Coiled-coil domain containing 58 | CCDC58 | 5.5                        | 0.003 | −1.48     |        |          |        |        |
| NM_080737    | Synaptotagmin-like 4           | SYTL4  | 6.3                        | 0.043 | −1.49     |        |          |        |        |
| NM_153010    | CHST9 antisense RNA 1 (non-protein coding) | CHST9-AS1 | 6.7                        | 0.017 | −1.59     |        |          |        |        |
| NM_024854    | Pyridine nucleotide-disulphide oxidoreductase domain 1 | PYROXD1 | 9.6                        | 0.022 | 1.56      |        |          |        |        |
| NM_000853    | Glutathione S-transferase theta 1 | GSTT1  | 5.6                        | 0.014 | 1.43      |        |          |        |        |

F-change indicates fold change in the MDD group as compared to the C group. Significant (p < 0.05) changes are indicated in bold; those that exhibited a trend toward significance (p < 0.1) are italicized. Correlations between microarray and qPCR results are also presented; r, Pearson's r correlation coefficient.

and qPCR results (Jain et al., 2005; Guilloux et al., 2011). Individual z-scores were calculated by normalizing differences between each data point and the mean of the C group to the standard deviation of the C group. Within subject microarray and qPCR z-scores were averaged for each gene, and this average z-score was then used for group comparisons. This analysis revealed significant (p < 0.05) downregulation in the expression of TOB1, NR4A2, and ADM in MDD-subjects, and a trend (p < 0.1) for downregulation for EGR1, as compared to C subjects (Figure 5). In the MDD + SSRI group, we observed significant (p < 0.05) downregulation in the expression of ADM, and a trend for downregulation in EGR1 (p = 0.1) and NR4A2 (p = 0.1), as compared to the C group.

DISCUSSION

This study examined DR in post-mortem brains from patients diagnosed with MDD and from psychiatrically normal comparison subjects. We utilized the ISH-guided LCM approach to collect DR samples, because our previous studies validated this approach in gene expression studies in postmortem human brain tissue (Bernard et al., 2009, 2011). This method combines a high level of anatomical resolution with more precise tissue sampling, which enriches specific mRNAs and improves sensitivity and the dynamic range of microarray-based gene expression profiling (Bernard et al., 2009). We also chose to look at the entire region of DR within each section rather than capturing individual neurons, because previous studies indicate the importance of the entire cellular milieu of the DR, including neurons of different neurochemical content (i.e., 5-HT and non-5-HT containing; Lemos et al., 2006). Other studies have also highlighted the importance of glia and glial-neuronal interaction in normal brain function, as well as in MDD, in multiple cortical and subcortical brain regions (Rajkowska and Miguel-Hidalgo, 2007; Bernard et al., 2011; Parpura et al., 2012). Our microarray data suggest that a number of functional gene networks are altered in the DR in MDD brain. These include: biosynthesis and metabolism, axonal guidance, mitochondrial dysfunction and oxidative stress, cell cycle regulation, and intracellular signaling and transcriptional regulation. Of these functional groups, genes with the largest changes in expression belonged to the transcriptional regulation group, and subsequent qPCR validation confirmed the downregulation in the expression of EGR1, TOB1, and NR4A2. These changes did not appear to be due to medication effects, and
functional pathway analysis of the microarray data revealed alterations in the expression of several downstream targets of these transcriptional regulators. Our preliminary anatomical studies suggest that EGR1 and NR4A2, as well as ADM (a downstream target of NR4A2 that was also significantly downregulated in MDD), are widely expressed, but are enriched in their expression within the DR. These observations suggest transcriptional alterations within multiple cell types in the DR, which may have diverse functional consequences on its function.

LIMITATIONS
As in all post-mortem human brain investigations, our study has several methodological limitations. Most importantly, one needs to be aware that our observations are correlational, and thus we cannot know from our data whether these molecular alterations contribute to the emergence of MDD or are its consequence. Nonetheless, our data are consistent with other studies that have implicated EGR1, NR4A2, and TOB1 in a number of functional processes that are dysregulated in neuropsychiatric disorders (see below).

We focused on gene expression at the middle-caudal portion of the DR, because 5-HT neurons within the rostral DR are more likely to project to motor targets, while those located more caudally are enriched in their projections to the forebrain limbic targets, including hippocampus and lateral septum (Wyss et al., 1979; Waselus et al., 2006). These limbic nuclei play an important role in reward and memory function, which are impaired in MDD. Previous post-mortem studies also reported gene expression alterations in the DR of depressed suicides, with the largest differences within its middle-caudal portion (Bach-Mizrachi et al., 2006, 2008). Taken together, these studies suggest that the middle-caudal DR plays an important role in affective regulation and is specifically impacted in MDD. Future work will be required to determine whether gene expression changes that we observed in this DR subregion extend to its more rostral subdivisions.

Subjects included in our study were severely depressed at the time of death. Nearly half of them committed suicide, which was likely related to their depression. Therefore, it may be that our observed gene expression changes are not present in mildly or moderately depressed individuals. In addition, in most post-mortem studies of neuropsychiatric diseases it is very difficult to determine whether observed effects are due to the illness itself, or due to the medications used to treat the disease. To address this issue we parsed MDD subjects into those who were and into those who were not prescribed SSRIs at the time of death. This analysis demonstrated significant downregulation in the expression of TOB1, NR4A2, and ADM, and a trend toward significance for EGR1, in the latter group relative to the controls. Though we cannot rule out potential impact of other drugs, these results suggest that our observations are not due to SSRIs, the most common medications used to treat MDD. Nonetheless, the observed alterations in gene expression need to be replicated in an independent cohort of subjects to increase confidence in our results.

We designed the present study to examine gene expression alterations within the entire cellular milieu of the middle-caudal DR. The advantage of this approach is that we were able to: (1) target the portion of the DR that regulates limbic functions, (2)
FIGURE 3 | Downstream gene targets of TOB1, EGR1, and NR4A2 that were altered in their expression in the MDD group as compared to the C group. Genes were included in this analysis if: (1) they were detected in ≥50% of arrays in either the MDD or C group, (2) their changes in expression were ≥ 1.1- or ≤−1.1-fold in magnitude, and (3) associated p-values < 0.05. Gene-gene interactions were analyzed using Ingenuity Pathway Analysis knowledge database. Marked in red are gene products that were upregulated, while those in green were downregulated.

examine gene expression alterations within multiple cell types, and (3) identify functional pathways most strongly impacted by MDD. However, the drawback of this approach is that it lacks cellular resolution and we cannot know whether these gene expression changes impact a variety of cell types within the DR, or if they are restricted to a particular functional class. Future studies that utilize single cell analyses will be required to address this issue.

FUNCTIONAL PATHWAYS ALTERATIONS
Pathway analysis of the microarray data revealed dysregulation in the DR of MDD patients within several functional gene groups, including those that regulate: biosynthesis, metabolism, axon guidance, mitochondrial function, intracellular signaling, transcription, oxidative stress response, and the cell cycle. These data suggest that a defined set of cellular functions are dysregulated in the DR in MDD, including: (1) intracellular stress and energy balance, (2) intracellular signaling and transcriptional regulation, and (3) cell proliferation and connectivity.

Previous studies have implicated these, or related, functional groups in the pathophysiology of mood disorders in other brain regions. For example, decreased cell proliferation may contribute to the decrease in the numbers of glial cells and glial markers within cortical and subcortical brain regions in the depressed brain (Rajkowska, 2003; Rajkowska and Miguel-Hidalgo, 2007; Bernard et al., 2011). Likewise, increased hippocampal neurogenesis has been proposed to underlie the mechanism of antidepressant action (Perera et al., 2007; Boldrini et al., 2009). Alterations in the expression of cell connectivity markers are consistent with imaging reports demonstrating alterations in resting-state connectivity among several limbic brain regions in MDD (Fingelkurts et al., 2007; Greicius et al., 2007). Mitochondrial dysfunction and impaired intracellular stress response have also been implicated in the emergence of bipolar disorder and depression (Rezin et al., 2009). Taken together with our data, these observations suggest that MDD is associated with the dysregulation of a set of functional pathways across multiple brain regions. Future work will be required to determine how these alterations impact specific cell types and circuits, and how these functional changes mediate clinical manifestations of mood disorders.

TRANSCRIPTIONAL DYSREGULATION IN THE DR
Cellular transcription is a process that is tightly controlled by DNA-binding factors that regulate a variety of process, such as neurodevelopment, adaption to environmental cues, intracellular...
In situ hybridizations for EGR1, ADM, and NR4A2. Tissue was processed for radioactive ISHs as previously described (Lopez-Figueroa et al., 2004; Bernard et al., 2009), using the following probes: EGR1, accession # NM_001964, pos. 857–1495; ADM, accession # NM_001124, pos. 701–1349; NR4A2, accession # NM_NM_173173, pos. 344–669. Binding with antisense (left column) and sense (right column) riboprobes is illustrated to compare specific and non-specific binding. Arrows indicate location of the dorsal raphe; compare to signal in Figures 1I–L. Note the presence of specific signal that is enriched within the DR in the antisense images, but is absent in the sense ones.

FIGURE 4 | In situ hybridizations for EGR1, ADM, and NR4A2. Tissue was processed for radioactive ISHs as previously described (Lopez-Figueroa et al., 2004; Bernard et al., 2009), using the following probes: EGR1, accession # NM_001964, pos. 857–1495; ADM, accession # NM_001124, pos. 701–1349; NR4A2, accession # NM_NM_173173, pos. 344–669. Binding with antisense (left column) and sense (right column) riboprobes is illustrated to compare specific and non-specific binding. Arrows indicate location of the dorsal raphe; compare to signal in Figures 1I–L. Note the presence of specific signal that is enriched within the DR in the antisense images, but is absent in the sense ones.

signaling, cell cycle control, and others (Collins et al., 1995; Cho et al., 2001; Lonze and Ginty, 2002). Thus, in the intracellular signaling chain, transcriptional regulators are at the cusp between the effects of an external stimulus and its impact on cellular function. Altered transcriptional control can result in dysregulated expression of a host of downstream genes, and such changes have been observed in cancer, autoimmune diseases, diabetes as well as in neuropsychiatric disorders (Abraham and Kroeger, 1999; Black et al., 2001; Habener et al., 2005; Monteggia and Kavalali, 2009; Robison and Nestler, 2011). Many of these studies report global transcriptional alterations, but local circuitries may contain yet undetected defects in transcriptional control. Indeed, upregulation in the expression of NUDR and REST, both of which are 5-HT-related transcriptional regulators, have been recently reported within serotonergic neurons in the DR (Goswami et al., 2010). Interestingly, these changes were sex-dependent and were only apparent in female subjects. Here we report that among the DR transcripts that exhibited the most significant and largest expression differences in MDD, there are three transcription factors: TOB1, NR4A2, and EGR1.

Because these genes are transcriptional regulators, we used functional pathway analysis to identify changes in expression of their downstream targets. This approach revealed alterations in the expression of several downstream targets in our microarray data set. These included other transcriptional regulators: NR4A3, THRA, THRβ, and CSDA. In addition to these direct transcriptional regulators, we also observed a downregulation in the expression of GADD45B, a downstream target of EGR1 and an epigenetic regulator that mediates activity-dependent DNA demethylation (Ma et al., 2009). These observations suggest alterations in transcriptional regulation via changes in the expression of factors that bind directly to the genome, as well as those that mediate epigenetic regulation of gene expression.

Analysis of downstream targets also revealed downregulation in the expression of CCND2 and CCNE2, downstream targets of EGR1 and TOB1, respectively. Both of these genes are part of the cell cycle regulation group, which we observed as significantly altered using functional pathway analysis (Table 3). We also detected a downregulation in the expression of PPP1R3C, downstream of EGR1, and that of ADM, downstream of NR4A2, both of which were among the genes that showed that largest changes in expression (Table 4). ADM is a widely expressed peptide that exerts its actions via a G protein coupled receptor, which when activated triggers a second messenger cascade that regulates gene transcription (Cuttitta et al., 2002). Altered expression of ADM has been previously correlated with mood disorders, while its knock-out in mice leads to heightened anxiety-like behavior (Savas et al., 2002; Fernandez et al., 2008; Huang et al., 2010). In addition, a recent study has identified NR4A2 as a regulator of EGR1 expression, raising the possibility that these transcriptional regulators also directly interact with each other (Johnson et al., 2011).

Previous studies have implicated alterations in the expression or function of EGR1, NR4A2, and TOB1 in brain processes impacted by MDD. For example, TOB1 expression is altered in the frontal cortex of patients with bipolar disorder (Bezchlibnyk et al., 2001), while molecular interference with the TOB1 protein suppresses long-term potentiation and impairs spatial learning and memory in rats (Jin et al., 2005). Previous work has demonstrated that TOB-interacting proteins play a role in neuronal differentiation, suggesting that TOB1 is expressed in neurons (Berthet et al., 2002). TOB1 plays a fundamental role in cell proliferation and growth (Mackawa et al., 2002), and it is feasible that its dysfunction may lead to morphological changes observed in the DR of MDD patients (Baumann et al., 2002).

Studies focused on NR4A2 have demonstrated its importance in the genesis of dopaminergic neurons (Ojeda et al., 2003; Galleguillos et al., 2010). In addition to the decrease in NR4A2
expression, functional pathway analysis of our data also revealed an upregulation in the expression of the dopamine transporter (SLC6A3; Figure 3). DR contains a large number of catecholaminergic neurons that give rise to ascending projections to nucleus accumbens, prefrontal cortex, and the lateral septum, key areas in the regulation of affect and reward (Stratford and Wirtshafter, 1990; Michelsen et al., 2007). Taken together, these observations suggest that functional alterations of ascending catecholamine circuits from the DR may contribute to the etiology of MDD. Consistent with this notion is the observation that mice with reduced NR2A exhibit alterations in forebrain levels of dopamine and 5-HT along with increased immobility on the forced swim test, a measure of learned helplessness and a core feature of MDD (Rojas et al., 2010).

EGR1 is a transcriptional switch that regulates a number of diverse gene targets. It is an immediate-early gene that gets activated in response to a variety of stimuli, including drug administration that leads to 5-HT release (Humblot et al., 1998). Previous work indicates that it is strongly expressed in neurons in the adult brain, and that its levels are altered by neurotransmitter release and neuronal activation (Knapska and Kaczmarek, 2004). It can also exert long-lasting changes in gene expression and subsequent protein synthesis that mediate synaptic plasticity. EGR1 has been implicated in mediating a variety of behaviors that are dysregulated in MDD, including learning and memory, fear conditioning, drug addiction, and social interaction (Cole et al., 1989; Ressler et al., 2002; Malkani et al., 2004; Valjent et al., 2006; Stack et al., 2010). Extensive evidence also implicates 5-HT signaling in mediating neuroplasticity, such as functional plasticity in the cortex following sensory deprivation (Maya Vetencourt et al., 2008; Jitsukui et al., 2011). These observations raise the possibility that altered EGR1 expression in the DR may lead to disruption of 5-HT-mediated plasticity within the limbic forebrain regions.

A recent report has documented a decrease in the cross-sectional area of the DR in MDD (Matthews and Harrison, 2012). This observation may be due to a variety of factors, including decreased numbers of neurons or glia, or decreased density of synaptic inputs or diminished dendritic branching of DR neurons. Given that TOB1 and NR2A play an important role in neuronal differentiation, it is feasible that alterations in their expression may contribute to morphological alterations within the DR associated with MDD.

CONCLUSION
Transcriptional regulators mediate a number of brain functions and behaviors that are dysregulated in MDD, including learning and memory, fear consolidation, and cognitive function (Morris et al., 1988; Ressler et al., 2002; Malkani et al., 2004). Transcriptional dysregulation has also been previously implicated in the etiology of diverse neuropsychiatric disorders such as Rett syndrome,

![Figure 5](https://example.com/figure5.png)

**FIGURE 5** | Effect of SSRI treatment on gene expression. Within subject microarray and qPCR z-scores were combined for each gene: EGR1 (A), TOB1 (B), NR4A2 (C), and ADM (D). Data are shown as Mean ± SEM for: Control subjects (n = 8), MDD subjects not treated with SSRIs (MDD−; n = 8) at the time of death, and MDD subjects treated with SSRIs (MDD + SSRI; n = 5) at the time of death (see text for more details).
addiction, schizophrenia, bipolar disorder, and MDD (Law et al., 2006; Monteggia and Kavalali, 2009; Goswami et al., 2010; Soria et al., 2010; Robison and Nestler, 2011). Because of its key role in central 5-HT neurotransmission and extensive evidence for its functional and structural alterations in mood disorders, along with similar alterations in rodent models of depression, the DR likely plays a key role in the pathophysiology of MDD. Our data point to the dysregulation of multiple transcriptional regulators in the DR, including: (1) transcription factors that directly bind to the genome in response to upstream gene activation or environmental cues (i.e., EGR1, TOB1, and CSDA), (2) ligand-activated nuclear receptors that regulate transcription via their genomic actions (NR4A2, NR4A3, THR-A and THR-B), (3) an epigenetic regulator (GAD45B), and (4) a peptide that regulates transcription via its binding to a G protein coupled receptor and downstream activation of intracellular signaling (ADM). These observations suggest alterations in the function of a host of downstream targets, which may lead to the dysregulation of multiple cellular functions that contribute to the pathophysiology of MDD. Future studies will require single cell analyses in the DR to determine potential impact of these changes on its cellular functions and related circuits. One approach would be to use data from previous studies that used microarrays to fingerprint individual classes of cells in the brain (Ponomarev et al., 2006). However, since such data are not available for the human brainstem, studies utilizing single cell LCM in the postmortem human brain will be required (Goswami et al., 2010; Ordway et al., 2012).

ACKNOWLEDGMENTS
This work was supported by Pritzker Neuropsychiatric Disorder Research Consortium and by NIMH Conte Center grant L99MH60398. Ilan A. Kerman is supported by NIH grant 5R00MH81927-04 and by the NARSAD Young Investigator Award from the Brain & Behavior Research Foundation. We thank Sharon Burke, Jennifer Fitzpatrick, and Mary Hoversten for their expert technical assistance. We are grateful to Drs. David Crossman and Xiangqin Cui for help with data analysis, and to Dr. Holly Moore for helpful discussions related to data analysis and interpretation.

The authors are members of the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C. A shared intellectual property agreement exists between this philanthropic fund and the University of Michigan, Stanford University, the Weill Medical College of Cornell University, and the Universities of California at Davis and at Irvine to encourage the development of appropriate findings for research and clinical applications.

DISCLAIMER
This work was performed as part of the Pritzker Neuropsychiatric Disorders Research Consortium (http://www.pritzkerneuropsych.org/), a large multi-site effort dedicated to uncovering neurobiological underpinnings of neuropsychiatric diseases. The data presented are part of a much larger data set, which is still being mined by the Consortium for other aspects of gene expression alterations from the major depressive cohort. The raw microarray data are not being released as part of this paper. However, the Consortium is planning a large release of the raw microarray data from multiple brain regions in the postmortem human tissue. A list of differentially expressed genes detected in this study is included in Supplemental Materials.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at http://www.frontiersin.org/Neurogenomics/10.3389/fnins.2012.00135/abstract

REFERENCES
Abraham, L. J. and Kroeger, K. M. (1999). Impact of the −308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J. Leukoc. Biol. 66, 562–566.
Abrams, J. K., Johnson, P. L., Hollis, J. H., and Lowry, C. A. (2004). Anatomic and functional topography of the dorsal raphe nucleus. Ann. N. Y. Acad. Sci. 1018, 46–57.
Arango, V., Underwood, M. D., Boldrini, M., Tamir, H., Kasir, S. A., Hsiung, S., et al. (2001). Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25, 892–903.
Arango, V., Underwood, M. D., and Mann, J. J. (1996b). Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. Alcohol. Clin. Exp. Res. 20, 1141–1147.
Arango, V., Underwood, M. D., and Mann, J. J. (2002). Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 136, 443–453.
Atz, M., Walsh, D., Cartagena, P., Li, J., Evans, S., Choudary, P., et al. (2007). Methodological considerations for gene expression profiling of human brain. J. Neurosci. Methods 163, 295–309.
Armita, E. C. (1999). Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Neuropsychopharmacology 23, 355–355.
Bach-Mizrachi, H., Underwood, M. D., Tin, A., Ellis, S. P., Mann, J. J., and Arango, V. (2008). Elevated expression of tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides. Mol. Psychiatry 13, 507–513, 465.
Baumann, B., Bielau, H., Krell, D., Agelink, M. W., Diekmann, S., Wurthmann, C., et al. (2002). Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. Psychiatr. Med. 32, 93–103.
Bernard, R., Kerman, I. A., Meng, F., Evans, S. J., Amrein, I., Jones, E. G., et al. (2009). Gene expression profiling of neurochemically defined regions of the human brain by in situ hybridization-guided laser capture microdissection. J. Neurosci. Methods 178, 46–54.
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., et al. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 16, 634–646.
Berthet, C., Guenhennec, F., Revol, V., Samaout, C., Lukasiewicz, A., Deyhy, C., et al. (2002). Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells 7, 29–39.
Bezchlibnyk, Y. R., Wang, J. F., McQueen, G. M., and Young, L. T. (2001). Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J. Neurochem. 79, 826–834.
Black, A. R., Black, J. D., and Arizkhan-Clifford, J. (2001). Spi1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188, 143–160.
Blier, P. (2001). Noradrenergic and selective norepinephrine reuptake inhibitors in depression and mood disorders: their pivotal roles. J. Psychiatry Neurosci. 26(Suppl.), S1–S2.
Dai, M., Wang, P., Boyd, A. D., Kos- 
tov, G., Athey, B., Jones, E. G., et al. (2005). Evolving gene/transcrip-
tion definitions significantly alter the interpretation of GeneChip data.
Nucleic Acids Res. 33, e175.

Dheda, K., Huggett, J. F., Chang, J. S., 
Kim, L. U., Bustin, S. A., Johnson, 
M. A., et al. (2005). The implications of using an inappropriate reference 
gene for real-time reverse transcription PCR data normalization. Anal.
Biochem. 344, 141–143.

Evans, S. J., Choudary, P. V., Neal, C. R., 
Li, J. Z., Vawter, M. P., Tomita, H., et al. (2004). Dysregulation of the 
fibroblast growth factor system in major depression. Proc. Natl.
Acad. Sci. U.S.A. 101, 15506–15511.

Fernandez, A. P., Serrano, J., Tessarollo, 
L., Cuttitta, E., and Martinez, A. (2008). Lack of adenomedullin in the 
mouse brain results in behavioral changes, anxiety, and lower survival 
under stress conditions. Proc. Natl. 
Acad. Sci. U.S.A. 105, 12581–12586.

Fingelkurts, A. A., Rytasla, H., Suomii-
nen, K., Isometsa, E., and Kahkonen, 
S. (2007). Impaired functional con-
nectivity at EEG alpha and theta fre-
quency bands in major depression.

Hum. Brain Mapp. 28, 247–261.

Frank, E., and Thase, M. E. (1999). Nat-
ural history and preventative treat-
ment of recurrent mood disorders.

Ann. Rev. Med. 50, 453–468.

Galleguillos, D., Fuentealba, J. A., 
Gomez, L. M., Sarea, M., Gomez, A., 
Nash, K., et al. (2010). Nur1 reg-
ulates RET expression in dopamine 
neurons of adult rat midbrain.

J. Neurochem. 114, 1158–1167.

Goodwin, F. K., and Bunney, W. E. Jr. 
(1971). Depressions following reser-
pin: a reevaluation. Semin. Psychia-
try 3, 435–448.

Goswami, D. B., May, W. L., Stockmeier, 
C. A., and Austin, M. C. (2010). 
Transcriptional expression of sero-
tonergic regulators in laser-capture 
miкусdissected dorsal raphe 
neurons of subjects with major 
depressive disorder: sex-specific 
differences. J. Neurochem. 112, 
397–409.

Greicius, M. D., Flores, B. H., Menon, V., 
Glover, G. H., Sallows, H. B., Kenna, 
H., et al. (2007). Resting-state func-
tional connectivity in major depres-
sion: abnormally increased contri-
butions from subgenual cingulate corti-
cal subregions. Biol. Psychiatry 
62, 429–437.

Guiloux, J. P., Sereny, M., Edgar, N., 
and Sibille, E. (2011). Integrated behav-
ioral z-scoring increases the sensi-
tivity and reliability of behavioral 
phenotyping in mice: relevance to 
emotionality and sex. J. Neurosci.
Methods 197, 21–31.

Habener, J. F., Kemp, D. M., and 
Thomas, M. K. (2005). Minireview: 
transcriptional regulation in pan-
creatic development. Endocrinology 
146, 1025–1034.

Hirschfeld, R. M. (2000). History 
and evolution of themonoamine 
hypothesis of depression. J. Clin.
Psychiatry 61(Suppl. 6), 4–6.

Huang, J., Perlis, R. H., Lee, P. F., Rush, 
A. J., Fava, M., Sachs, G. S., et al. 
(2010). Cross-disorder genomewide 
analysis of schizophrenia, bipolar 
disorder, and depression. Am. J. 
Psychiatry 167, 1254–1263.

Humbolt, N., Thiriet, N., Goballe, S., 
Aunis, D., and Zwiller, J. (1998). The 
serotonic system modulates 
the cocaine-induced expression of 
the immediate early genes egr-1 and c-
fos in rat brain. Ann. N. Y. Acad. 
Sci. 844, 7–20.

Jain, A., Nandankumar, K., and Ross, A. 
(2005). Score normalization in mul-
timodal biometric systems. Pattern 
Recognit. 38, 2270–2285.

Jin, M., Wang, X. M., Tu, Y., Zhang, X. 
H., Gao, X., Guo, N., et al. (2005). 
The negative cell cycle regulator, 
Tob (transducer of ErbB-2), is a 
multifunctional protein involved in 
hippocampus-dependent learning and 
memory. Neuroscience 131, 
647–659.

Jitsuki, S., Takemoto, K., Kawasaki, T., 
Tada, H., Takahashi, A., Becelam, 
C., et al. (2011). Serotonin mediates 
cross-modal reorganization of corti-
cal circuits. Neuron 69, 780–792.

Johnson, M. M., Michelhaugh, S. K., 
Bouhamdan, M., Schmidt, C. J., and 
Rannon, M. J. (2011). The transcription factor NURR1 
exerts concentration-dependent 
effects on target genes mediat-
ing distinct biological processes.
Front. Neurosci. 5:135. doi:10.3389/ 
fnins.2011.00135.

Kerman, I. A., Clinton, S. M., Simpson, 
N. D., Besdrosian, T. A., Bernard, R., 
Akl, H., et al. (2012). Inborn differ-
fences in environmental reactivity 
predict differential diurnal behavioral, 
dendritic, and gene expression 
rythms. Psychooncologer 
37, 256–269.

Kessler, R. C., Berglund, P., Demler, O., 
Jim, R., Koretz, D., Merikangas, 
K. R., et al. (2003). The epidemi-
ology of major depressive disorder: 
results from the National Comor-
bidity Survey Replication (NCS-R).
JAMA 289, 3095–3105.

King, J. Y., Ferrara, R., Tabibiazar, R., 
Spin, J. M., Chen, M. M., Kuchin-
sky, A., et al. (2005). Pathway analysis 
of coronary atherosclerosis. Physiol.
Genomics 23, 103–118.

Klimke, V., Stockemeier, C., Overholser, 
J., Meltzer, H. Y., Kalka, S., Dilley, 
G., et al. (1997). Reduced levels of 
norepinephrine transporters in the 
locus coeruleus in major depression.
J. Neurosci. 17, 8451–8458.

Koopaka, E., and Kaczmarek, L. (2004). 
A gene for neuronal plasticity in the 
mammalian brain: Zif268/Egr-
1/NFGF/A-Krox-24/TKS/ZENK? 
Prog. Neurobiol. 74, 183–211.

Lapin, I. P., and Osenkrug, G. F. (1969). 
Inhibition of the central serotoninergic 
processes as a possi-
bile determinant of the thyroemetic 
effect. Lancet 1, 132–136.

Law, A. J., Lipska, B. K., Weickert, 
C. S., Hyde, T. M., Straub, R. E., 
Hashimoto, R., et al. (2006). Neureg-
ulin 1 transcripts are differentially 
expressed in schizophrenia and reg-
ulated by 5’ SNPs associated with the 
disease. Proc. Natl. Acad. Sci. U.S.A. 
103, 6747–6752.

Lee, H. S., Kim, M. A., Valentinio, R. L., 
and Waterhouse, B. D. (2003). Gluta-
materefferent projections to the 
dorsal raphe nucleus of the rat. 
Brain Res. 963, 57–71.

Lemos, J. C., Pan, Y. Z., Ma, L., Lamy, 
C., Akarwa, A. C., and Beck, S. 
G. (2006). Selective 5-HT recep-
tor inhibition of glutamatergic and 
GABAergic synaptic activity in the 
rat dorsal and median raphe. Eur. 
J. Neurosc. 24, 3415–3430.

Leonard, B. E. (2000). Evidence for 
a biochemical lesion in depression. 
J. Clin. Psychiatry 61(Suppl. 6), 
12–17.

Li, J., Vawter, M. W., Walsh, D., Tomita, 
H., Evans, S., Choudary, P. V., et al. 
(2004). Systematic changes in gene 
expression in postmortem human brains 
associated with tissue pH and termi-
nal medical conditions. Hum. 
Mol. Genet. 13, 609–616.

Libuz, I., and Stonchova, H. (2006). 
Quantification of cDNA generated by reverse transcription of total RNA 
provides a simple alternative tool 
for quantitative RT-PCR normaliza-
tion. BioTechniques 41, 156, 158, 160 
passim.

Lonne, B. E., and Ginty, D. D. (2002). 
Function and regulation of CREB 
family transcription factors in the 
nervous system. Neuro 
35, 605–623.

Lopez-Figueroa, A. L., Norton, C. S., 
Lopez-Figueroa, M. O., Armellini-
Dodel, D., Burke, S., Akl, H., et al. 
(2004). Serotonin 5-HT1A, 5-
HT1B, and 5-HT2A receptor mRNA 
expression in subjects with major 
depression, bipolar disorder, and
schizophrenia. *Biol Psychiatry* 55, 225–233.

Lowry, C. A., Evans, A. K., Gasser, P. J., Hale, M. W., Staub, D. R., and Shekhar, A. (2008). “Topochemical organization and choreoarchitecture of the dorsal raphe nucleus and the median raphe nucleus,” in *Serotonin and Sleep: Molecular, Functional and Clinical Aspects*, eds J. M. Monti, S. R. Pandi-Perumal, B. L. Jacobs, and D. J. Nutt (Zurich: Birkhäuser Verlag), 25–67.

Ma, D. K., Jiang, M. H., Guo, J. U., Kitabatake, Y., Chang, M. L., Pow-Anpongkul, N., et al. (2009). Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science* 323, 1074–1077.

Maekawa, M., Nishida, E., and Tanoue, M., Ojeda, V., Fuentealba, J. A., Galleguillos, S., Malkani, S., Wallace, K. J., Donley, M. Maekawa, M., Nishida, E., and Tanoue, M. J., Ojeda, V., Fuentealba, J. A., Galleguillos, S., Malkani, S., Wallace, K. J., Donley, M., Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J. Maekawa, M., Nishida, E., and Tanoue, M. J., Jang, M. H., Guo, J.

Frontiers in Neuroscience | Neurogenomics

Kerman et al. Dorsal raphe transcriptional dysregulation in depression

Viegi, A., Baroncelli, L., De Lauretis, M., Nutt, D. J. (2007). Gliogenesis and glial differentiation in the substantia nigra after 6-hydroxydopamine lesion in the rat. *J Neurosci Res.* 88, 2284–2293.

Rozen, S., and Skatesky, H. J. (2000). “Primer3 on the WWW for general users and for biologist programmers,” in *Bioinformatics Methods and Protocols: Methods in Molecular Biology*, eds S. Krawetz and S. Misener (Totowa, NJ: Humana Press), 365–386.

Savas, H. A., Herken, H., Yurekli, M., Us, E., Tutkan, H., Zoroglu, S. S., et al. (2002). Possible role of nitric oxide and adenommedullin in bipolar affective disorder. *Neuropsychopharmacol. 45*, 57–61.

Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am. J. Psychiatry* 122, 509–522.

Schoor, O., Weinschenk, T., Hennenlotter, J., Corvin, S., Stenzl, A., Rammensee, H. G., et al. (2003). Moderate degradation does not preclude microarray analysis of small amounts of RNA. *BioTechniques 35*, 1192–1196, 1198–1201.

Soria, V., Martinez-Amoros, E., Escaramis, G., Valero, J., Perez-EGea, R., Garcia, C., et al. (2010). Differential association of circadian genes with mood disorders: CRY1 and Npas2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. *Neuropsychopharmacology 35*, 1279–1289.

Stack, A., Carrier, N., Dietz, D., Hollis, F., Sorenson, J., and Kabbaj, M. (2010). Sex differences in social interaction in rats: role of the immediate-early gene zif268. *Neuropsychopharmacol. 35*, 570–580.

Stratford, T. R., and Wirtshafter, D. (1999). Ascending dopaminergic projections from the dorsal raphe nucleus in the rat. *Brain Res. 513*, 173–176.

Taylor, V., and MacQuen, G. (2006). Associations between bipolar disorder and metabolic syndrome: a review. *J. Clin. Psychiatry 67*, 1034–1041.

Tolima, H., Vawter, M. P., Walsh, D. M., Evans, S. J., Choudary, P. V., Li, J., et al. (2004). Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analysis of postmortem human brain. *Biol. Psychiatry 55*, 346–352.

Underwood, M. D., Khabulina, A. A., Ellis, S. P., Moran, A., Rice, P. M., Mann, J. J., et al. (1999). Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. *Biol. Psychiatry 46*, 473–483.

Valjent, E., Aubier, B., Corbille, A. G., Brami-Cherrier, K., Caboche, I., Topilko, P., et al. (2006). Plasticity-associated gene Krox24/Zip168 is required for long-lasting behavioral effects of cocaine. *J. Neurosci. 26*, 4956–4960.

Wales, M., Galvez, J. P., Valentino, R. J., and Van Bockstaele, E. J. (2006). Differential projections of dorsal raphe nucleus neurons to the lateral septum and striatum. *J. Chem. Neuroanat. 31*, 233–242.

Wong, M. L., and Medrano, J. F. (2005). Real-time PCR for mRNA quantitation. *BioTechniques 39*, 75–85.

Wys, J. M., Swanson, L. W., and Cowan, W. M. (1978). A study of subcortical afferents to the hippocampal formation in the rat. *Neuroscience 4*, 463–476.

Zhu, M. Y., Klimczak, V., Dilley, G. E., Haycock, J. W., Stockmeier, C. A., Overholser, J. C., et al. (1999). Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. *Biol. Psychiatry 46*, 1275–1286.

Zuker, M. (2003). MiRNA web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res. 31*, 3406–3415.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 29 May 2012; accepted: 30 August 2012; published online: 18 October 2012.

Citation: Kerman IA, Bernard R, Bunney WE, Jones EG, Schatzberg AF, Myers RM, Barchas JD, Akil H, Watson SJ and Thompson RC (2012) Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder. Front. Neurosci. 6:135. doi: 10.3389/fnins.2012.00135

This article was submitted to Frontiers in Neurogenomics, a specialty of Frontiers in Neuroscience. Copyright © 2012 Kerman, Bernard, Bunney, Jones, Schatzberg, Myers, Barchas, Akil, Watson and Thompson. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.